



ජාතික ඖෂධ නියාමන අධිකාරිය  
தேசிய மருந்துகள் ஒழுங்குபடுத்தல் அதிகார சபை  
National Medicines Regulatory Authority

මගේ අංකය  
எனது இல.  
My No.

NMRA/PV/AWP/2025-01

ඔබේ අංකය  
உங்கள் இல.  
Your No.

දිනය  
திகதி  
Date

02.09.2025

Directors,  
National/Teaching Hospitals – Sri Lanka

**Subject: Invitation to Register the Virtual Awareness Program to Enhance Adverse Drug Reaction (ADR) Reporting.**

Dear sir/madam,

The National Medicines Regulatory Authority-Sri Lanka, through its Pharmacovigilance Division; is fundamentally committed to safeguarding public health by establishing a robust system for the continuous monitoring of drugs, a process in which the reporting of Adverse Drug Reactions (ADRs) plays an indispensable role.

Timely and accurate ADR reporting is not merely a regulatory requirement; it is a critical practice that allows us to identify potential risks and take necessary action to protect patients.


To strengthen this vital function within government hospitals, we have organized a comprehensive **virtual awareness program on 30<sup>th</sup> September 2025 at 10.00 AM**. This initiative is designed to equip your key staff members with the knowledge and standardized protocols necessary to contribute to a more efficient and reliable national drug safety monitoring network.

We kindly request **formal registration of relevant personnel** from your institution, including clinicians, pharmacists, and nurses, **on or before 27<sup>th</sup> September 2025** via the below registration link.

**Registration Link:** <https://forms.gle/HY4nHeF74vQS1kQ36>

Contact for Inquiries: [pa3@nmra.gov.lk](mailto:pa3@nmra.gov.lk)

Thank you

  
Dr. K. M. G. K. Bandara.  
Chief Executive Officer  
National Medicines Regulatory Authority.

**Dr. K.M.G.K. Bandara**  
MBBS, MSc, MD (Com. Med), MA (Sociology)  
Chief Executive Officer (Acting)  
National Medicines Regulatory Authority  
130, W.A.D Ramanayake Mawatha, Colombo 02.